

# Monash Absolute Investment Fund

(APIR MON0001AU)



6% p.a Target  
Distribution



Double Digit returns  
since inception



Long/Short  
Australian Equities



Proven Track  
Record<sup>1</sup>

## April 2023 Fund Update

In April, the Fund rose 7.0% (after fees). This compares to an increase of 1.9% for the S&P/ASX200 and a rise of 2.8% for the Small Ords.

During April there was a significant contribution from a number of our holdings. Our best contributor for the month was Telix (ASX: TLX) which rose by 47%. Other larger holdings that rose included Temple and Webster 17%, Lovisa 10%, Johns Lyng 6% and QBE 5% (ASX: TPW, LOV, JLG and QBE).

Our approach to investing seeks out mispriced companies that will benefit from a step change in earnings due to recurring business situations. This month Telix was a strong example of this.

Telix jumped following disclosure that it had achieved over \$100m in quarterly revenue and is now solidly cash flow positive. This is due to the success of its first imaging product in prostate cancer called Illuccix. Although Illuccix was only launched a year ago in the USA it has significant growth still to come in that market. It is yet to launch in any other large market. European approval is likely in the next 12 months. In April Telix also held a briefing on its plans for China.

Telix's second imaging product addresses renal cancer. It will likely be launched next year. It could be around 50% of the size of the opportunity for Illuccix. Telix is conducting a substantial amount of R&D. Several of its programs have a near term catalyst. The most significant of these is the first read out of the Stage 3 Global ProstACT program which is a prostate cancer therapy (rather than imaging).

We are able to justify the current Telix share price based on the Illuccix product alone, with the rest of the portfolio of program representing material blue sky potential.

Consumer Discretionary was the best performing sector in April, rising 6%. During the month RBA rate rises paused and news flow regarding the economy was encouraging; with retail data showing an improvement in sales of household goods and house prices having now risen for two consecutive months since February. This benefited our holdings in retailers, Temple & Webster and Lovisa, neither of which made trading updates during the month.

Over the last month we closed our 2 short positions and now temporarily have no shorts in the portfolio but we continue to evaluate short candidates.

## Return Summary<sup>1</sup> (after all fees)

1 Month	3 Months
+7.00%	+1.30%
1 Year	3 Years
+3.20%	+15.40% <sub>pa</sub>

This fund is appropriate for investors with "High" and "Very High" risk and return profiles. A suitable investor for this fund is prepared to accept high risk in the pursuit of capital growth with a medium to long investment timeframe. Investors should refer to the [TMD](#) for further information.

<sup>1</sup> Inception date is 2 July 2012. Past performance is not indicative of future performance.

# Monash Absolute Investment Fund

(APIR MON0001AU)

## Monthly Portfolio Metrics

Outlook Stocks (Long)	14 Positions: 64%
Outlook Stocks (Short)	0 Positions: 0%
Event, Pair and Group (Long)	5 Positions: 31%
Event, Pair and Group (Short)	1 Positions: 0%
Cash	5%
Gross Exposure	95%
Net Exposure	95%

## Return Summary Since Inception (after fees)<sup>2</sup>

CYTD	5.81%
FYTD	9.97%
1 Month	7.01%
3 Month	1.29%
6 Month	2.26%
1 Year	3.22%
2 Years (p.a.)	-0.19%
3 Years (p.a.)	15.42%
4 Years (p.a.)	11.53%
5 Years (p.a.)	11.61%
7 Years (p.a.)	7.58%
Since Inception (p.a.)	10.22%

## Portfolio Analytics Since Inception<sup>2</sup>

Sharpe Ratio	0.53
Sortino Ratio	0.93
Standard Deviation (p.a.)	16%
Positive Months	60%
Maximum Drawdown	-29%
Avg. Gross Exposure	91%
Avg. Net Exposure	79%
Avg. Beta	0.69

<sup>2</sup> Inception date 2 July 2012. Past performance is not indicative of future performance.

# Monash Absolute Investment Fund

(APIR MON0001AU)

## For all business development enquiries, please contact

Cameron Harris

P: +61 400 248 435

[cameron@gsmcapital.com.au](mailto:cameron@gsmcapital.com.au)

## For all investors enquiries, please contact

Apex Fund Services Pty Ltd,

P: 1300 133 451

or by email at [registry@apexgroup.com](mailto:registry@apexgroup.com)

For more information about MAIF and the strategy, please refer to the Monash Investors website at [www.monashinvestors.com](http://www.monashinvestors.com). You can also [follow us on Livewire here](#) or [subscribe to our updates here](#)

This document is prepared by Monash Investors Pty Limited ABN 67 153 180 333, AFSL 417 201 ("Monash Investors") as authorised representatives of Sanlam Private Wealth Pty Ltd ABN 18 136 960 775, AFSL 337 927 ("Sanlam") for the provision of general financial product advice in relation to the Monash Absolute Investment Fund ARSN 606 855 501 ("Fund") and authorised for release by The Trust Company (RE Services) Limited ABN 45 003 278 831, AFSL 235 150 ("Perpetual") as the responsible entity of, and issuer of units in the Fund. Monash Investors is the investment manager of the Fund. A Product Disclosure Statement ("PDS") dated 25 May 2022 together with a Target Market Determination ("TMD"), both issued by Perpetual, is available for the Fund at [www.monashinvestors.com](http://www.monashinvestors.com). You should obtain and consider the PDS and TMD for the Fund before deciding whether to acquire, or continue to hold, an interest in the Fund. The information provided is general information only and is not intended to provide you with financial advice, it does not consider your investment objectives, financial situation or particular needs. You should consider your own investment objectives, financial situation and particular needs before acting upon any information provided and consider seeking advice from a financial advisor if necessary. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. No company in Perpetual Group (Perpetual Limited ABN 86 000 431 827 and its subsidiaries) guarantees the performance of any fund or the return of an investor's capital.

Performance figures assume reinvestment of income. Past performance is not a reliable indicator of future performance. Comparisons are provided for information purposes only and are not a direct comparison against benchmarks or indices that have the same characteristics as the Fund. Monash Investors, Sanlam and Perpetual do not guarantee repayment of capital or any particular rate of return from the Fund and do not give any representation or warranty as to the reliability, completeness or accuracy of the information contained in this document. All opinions and estimates included in this document constitute judgments of Monash Investors as at the date of this document are subject to change without notice. Perpetual is not responsible for this document.

In relation to the target distribution, this is a target return only. There is no guarantee the Fund will meet its investment objective. The payment of a quarterly distribution is a goal of the Fund only and neither Monash Investors or Perpetual provide any representations or warranty (whether express or implied) in relation to the payment of any quarterly cash income. The Fund reserves the discretion to amend its distribution policy.

The rating issued 09/2021 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit [lonsec.com.au](http://lonsec.com.au) for ratings information and to access the full report. © 2020 Lonsec. All rights reserved.

The rating contained in this document is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person's particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.

The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) ("Zenith") rating (assigned MON0001AU June 2021) referred to in this document is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at <http://www.zenithpartners.com.au/RegulatoryGuidelines>.